Chemotherapy (MVPP) for Stage IIIB/IV Hodgkin’s disease with an assessment of prognostic factors
- 42 Downloads
Of all patients presenting with Hodgkin’s disease, in excess of 30% will have Clinical Stage (CS) IIIB or IV disease or will be found to have Pathologic Stage (PS) IIIB/IV disease following staging laparotomy. Prior to the use of combination chemotherapy with mustine, vincristine, procarbazine and prednisolone (MOPP) , the prognosis for such patients was bleak. With the advent of the MOPP regimen a high percentage of durable complete remissions could be obtained. The dramatic improvement in survival for these patients has, however, led to a popular misconception that advanced stage Hodgkin’s Disease is a readily curable malignancy. Unfortunately, despite drug and dosage alterations, little advance has been made in the 20 years since the introduction of MOPP and 30–40% of patients will die using currently available therapy [2–4].
KeywordsComplete Remission Remission Status Durable Complete Remission Total Patient Group Curable Malignancy
Unable to display preview. Download preview PDF.
- 1.DeVita VT and Serpick A (1967). Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Proc Amer Assoc Cancer Res 8:13.Google Scholar
- 2.Frei E III, Luce JK, Gamble JF et al. (1973). Combination chemotherapy in advanced Hodgkin’s disease: Induction and maintenance of remission. Ann Intern Med 79:376382.Google Scholar
- 4.Bonadonna G, Zucali R, Monfardini S et al. (1975). Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 36:252–259.Google Scholar
- 10.Porzig K, Portlock C, Robertson A et al. (1978). Treatment of advanced Hodgkin’s disease with B-CAVe following MOPP failure Cancer 41:1670–1675.Google Scholar
- 14.Cox DR (1972). Regression models and life tables. J Roy Stat Soc B. 34: 187–220.Google Scholar
- 16.Coltman CA (1981). Chemotherapy of advanced Hodgkin’s disease. Semin Oncol 7:155–173.Google Scholar